Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33)

The summary for the Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33): Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing technically innovative feasibility studies focused on the advanced development and validation of cancer-relevant technologies that address the issues related to pre-analytical variations in the collection, processing, handling, and storage of biospecimens or its derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or their derived samples for downstream molecular analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. This FOA solicits R33 applications; this mechanism is suitable for projects where proof-of-principle of the proposed technology or methodology has already been established and supportive preliminary data are available. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued is an example of a topic not appropriate for this solicitation and will be returned as non-responsive. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Mechanism of Support. This FOA will utilize the R33 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-CA-10-001 that solicits applications under the NIH Exploratory/Developmental R21 grant mechanism.

Federal Grant Title:	Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-10-002
Type of Funding:	Grant
CFDA Numbers:	93.393
CFDA Descriptions:	Cancer Cause and Prevention Research
Current Application Deadline:	Sep 30, 2010
Original Application Deadline:	Sep 30, 2010
Posted Date:	Oct 26, 2009
Creation Date:	Oct 26, 2009
Archive Date:	Oct 31, 2010
Total Program Funding:	$2,250,000
Maximum Federal Grant Award:	$300,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional); • Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required); • National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...; • Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...; • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...; • Pilot Studies in Pancreatic Cancer; • Cancer Prevention Research Small Grant Program; • Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...